Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report, precarious financial situation, and clinical progress with lead candidate Bexmarilimab. With upcoming BEXMAB read-outs and a planned larger share issue ahead, we abstain from making any changes in our valuation for now.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/